Opinion|Videos|April 11, 2025
Oral JAK Inhibitors’ Place in Atopic Dermatitis Guidelines
Experts discuss the current place of JAK inhibitors in atopic dermatitis management, highlighting their role as an effective oral treatment option within the broader spectrum of therapies, including topical treatments and biologics, depending on disease severity and patient needs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the current place in therapy for JAK inhibitors in atopic dermatitis management, particularly when considering the spectrum of treatment options, including topical therapies and biologics?
Advertisement
Related to this article
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.
Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.
Martina Porter, MD, of Beth Israel Deaconess Medical Center discusses unmet needs in HS and where oral povorcitinib fits among emerging options.
Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Advertisement
Advertisement
Trending on HCPLive
1
Zabopegdutide Improves Fibrosis, MASH Resolution at 48 Weeks
2
Asundexian Receives FDA Approval for Secondary Stroke Prevention
3
RNA Editing With WVE-006 Restores Functional AAT, Cuts Z-AAT in AATD
4
Efinopegdutide Improves MASH Resolution, Fibrosis in Phase 2b Trial
5